YOLFTbeta
NextCell Pharma AB

NextCell Pharma AB

NXTCL · ST · Healthcare / Biotechnology

0.24SEK+0.00 (+0.63%)

Price History

Full chart

Market Stats

Previous Close0.2385
Open0.245
Day Range0.239 – 0.2625
52-Week Range0.63 – 1.78
Volume776.94K
Market Cap115.85M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.43
Dividend Yield0.00%
Beta0.72
50-Day Avg1.07
200-Day Avg1.15

About

NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of stromal cell therapies in Sweden. Its lead drug candidate is ProTrans, a cell therapy with mesenchymal stromal cells for the treatment of autoimmune and inflammatory diseases, including type-1 diabetes. The company also operates Cellaviva, a stem cell bank; and QVance, the first dedicated provider of quality services for developers of advanced therapies. The company was incorporated in 2014 and is headquartered in Huddinge, Sweden.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Mathias Svahn Ph.D.
  • Employees24
  • HeadquartersKarolinska Institutet Science Park, Huddinge, Sweden, 141 57, Sweden
  • Websitehttps://www.nextcellpharma.com

Leadership

  • Dr. Mathias Svahn Ph.D.Founder & CEO · b. 1976
  • Mr. Eric GustafssonChief Financial Officer · b. 1986
  • Mr. Lindsay DaviesChief Scientific Officer & CEO of QVance · b. 1979
  • Mr. Edvard SmithChief Medical Officer & Director · b. 1951
  • Sofie Falk JanssonCEO of Cellaviva · b. 1986
  • Ms. Sofia SisayHead of Clinical Trials · b. 1981

Financials

Income Statement

Currency: SEK2015-08-312016-08-312017-08-312018-08-312019-08-312020-08-312021-08-312022-08-312023-08-312024-08-312025-08-31
Total Revenue6.96K809.01K517.20K655.41K1.81M3.56M3.91M5.59M10.11M10.66M10.94M
Growth (%)-+11523.65%-36.07%+26.72%+176.49%+96.71%+9.74%+42.86%+80.96%+5.45%+2.56%
Cost of Revenue5.05M5.87M3.19M8.83M15.82M13.94M18.44M27.85M11.00M15.22M46.81M
Gross Profit-5.04M-5.06M-2.67M-8.17M-14.01M-10.37M-14.53M-22.26M-884.83K-4.56M-35.87M
Gross Margin-72434.89%-625.84%-516.90%-1247.08%-773.13%-291.00%-371.36%-398.31%-8.75%-42.74%-327.98%
Operating Expense5.38M6.36M10.59M5.87M7.44M7.33M10.29M12.76M40.12M38.61M0
Operating Income-10.42M-11.43M-13.26M-14.05M-21.45M-17.70M-24.82M-35.02M-41.00M-43.17M-35.87M
Operating Margin-149736.24%-1412.36%-2563.96%-2143.19%-1183.86%-496.60%-634.48%-626.68%-405.42%-404.81%-327.98%
EBITDA-9.87M-11.11M-12.95M-13.73M-17.64M-17.28M-24.21M-34.10M-39.36M-40.99M-32.63M
EBITDA Margin-141863.78%-1373.87%-2503.17%-2095.41%-973.51%-484.85%-618.88%-610.10%-389.22%-384.31%-298.32%
Net Income-10.29M-11.41M-13.25M-14.03M-21.46M-17.69M-24.56M-34.08M-39.81M-41.96M-35.14M
Net Income Margin-147840.73%-1410.79%-2560.93%-2140.98%-1184.14%-496.24%-627.92%-609.88%-393.65%-393.45%-321.31%
Interest Expense1.38K1.27K1.90K16.22K7.79K8.84K7.57K13.53K2.81K1.36K2.60K
Interest Expense % of Total Revenue19.76%0.16%0.37%2.47%0.43%0.25%0.19%0.24%0.03%0.01%0.02%

Balance Sheet

Currency: SEK2015-08-312016-08-312017-08-312018-08-312019-08-312020-08-312021-08-312022-08-312023-08-312024-08-312025-08-31
Total Assets12.36M9.47M21.63M8.51M26.72M29.77M155.63M124.66M88.83M81.29M76.73M
Total Liabilities2.59M2.70M2.55M3.47M3.76M3.56M5.53M9.12M13.10M13.69M10.34M
Total Equity9.77M6.76M19.07M5.04M22.96M26.22M150.09M115.54M75.73M67.60M66.39M
Cash8.70M5.85M16.60M3.12M20.13M21.96M139.17M97.12M50.03M46.79M38.72M
Net Debt-8.70M-5.85M-16.60M-3.12M-20.13M-21.96M-139.17M-97.12M-50.03M-46.79M-38.72M

Cash Flow

Currency: SEK2015-08-312016-08-312017-08-312018-08-312019-08-312020-08-312021-08-312022-08-312023-08-312024-08-312025-08-31
Operating Cash Flow-7.76M-11.12M-14.82M-13.55M-22.13M-18.96M-25.58M-33.31M-43.83M-37.78M-38.86M
Investing Cash Flow-3.60M-142.13K-401.50K-401.50K-401.50K-590.01K-5.84M-9.37M-4.10M-83.51K-4.24M
Financing Cash Flow20.78M8.39M25.57M64.72K39.55M21.38M148.63M608.17K835.66K34.63M35.03M
Capital Expenditure3.60M142.13K396.50K396.50K396.50K787.11K725.93K7.59M4.10M82.92K4.18M
Free Cash Flow-11.36M-11.26M-14.82M-13.55M-22.53M-19.75M-26.30M-40.90M-47.92M-37.86M-43.05M
FCF to OCF146.33%101.28%100.00%100.00%101.79%104.15%102.84%122.79%109.35%100.22%110.76%

Earnings

Report DateOct 30, 2020Jan 29, 2021Apr 29, 2021Jul 30, 2021Oct 29, 2021Jan 28, 2022Feb 28, 2022May 31, 2022Aug 31, 2022Nov 30, 2022Feb 28, 2023May 31, 2023Aug 31, 2023Nov 30, 2023Feb 29, 2024May 31, 2024Aug 31, 2024Jan 29, 2025Apr 25, 2025Jul 24, 2025Oct 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate---------------------0.10---
EPS Actual-0.22-0.21-0.27-0.19-0.13-0.19-0.23-0.21-0.20-0.20-0.26-0.25-0.20-0.23-0.23-0.26-0.22-0.11-0.11-0.14-0.08-0.12-0.09-0.09
Surprise--------------------20.00%---
Timing-----Pre-market--------------After-hours---

Key Statistics & Ratios

Market Cap115.85M
Enterprise Value91.60M
Trailing P/E0.00
Forward P/E0.00
Price / Sales10.75
Price / Book2.32
EPS-0.43
Book Value0.372
Revenue (TTM)10.78M
Gross Profit (TTM)3.50M
EBITDA-40.08M
Profit Margin0.00%
Operating Margin-386.44%
Return on Equity-52.46%
Return on Assets-28.39%
Shares Outstanding111.39M
Shares Float101.65M
Beta0.72
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%